COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,802 Articles (22,527 medRxiv, 8,275 bioRxiv)

Most recent first Previous |  Page 861: Articles 8601-8610  | Next

The effect of job strain and worksite social support on reported side effects of COVID-19 vaccine: a prospective study of employees in Japan
Sasaki, N., Kuroda, R., Tsuno, K., Imamura, K., Kawakami, N.
10.1101/2022.02.24.22271484 — Posted: 2022-02-26
Loneliness and diurnal cortisol levels during COVID-19 lockdown: the roles of living situation, relationship status and relationship quality
Hopf, D., Schneider, E., Aguilar-Raab, C., Scheele, D., Ditzen, B., Eckstein, M.
10.1101/2022.02.25.22271461 — Posted: 2022-02-26
Waning Effectiveness of the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine
Patalon, T., Saciuk, Y., Peretz, A., Perez, G., Lurie, Y., Maor, Y., Gazit, S.
10.1101/2022.02.25.22271494 — Posted: 2022-02-26
Booster protection against Omicron infection in a highly vaccinated cohort
Tai, C., Maragakis, L. L., Connelly, S., DiFiori, J., Sims, L., Adams, E., Anderson, D., Merson, M., Ho, D., Grad, Y., Mack, C. D.
10.1101/2022.02.24.22271347 — Posted: 2022-02-26
Cross-neutralizing activity against Omicron could be obtained in SARS-CoV-2 convalescent patients who received two doses of mRNA vaccination
Kurahashi, Y., Furukawa, K., Sutandhio, S., Tjan, L. H., Iwata, S., Sano, S., Tohma, Y., Ohkita, H., Nakamura, S., Nishimura, M., Arii, J., Kiriu, T., Yamamoto, M., Nagano, T., Nishimura, Y., Mori, Y.
10.1101/2022.02.24.22271262 — Posted: 2022-02-26
Rapid genome surveillance of SARS-CoV-2 and study of risk factors using shipping container laboratories and portable DNA sequencing technology
FARAHI BILOOEI, S., Jovicevic, D., Iranzadeh, A., Mpofu, C., Muscat, I., Thomas, A., Steiner, H., Meany, T.
10.1101/2022.02.25.22271277 — Posted: 2022-02-26
Clinical and Virologic Factors associated with Outcomes of COVID-19 before and after Vaccination among Veterans: Retrospective Analysis from Six New England States
Lee, M., Cosenino, D., Kyriakides, T. C., Cavallaro, T., Stack, G., Gupta, S.
10.1101/2022.02.24.22271468 — Posted: 2022-02-25
Health Provider and Sexual and Gender Minority Service User Perspectives on Provision of Mental Health Services During the Early Phase of the COVID-19 Pandemic in British Columbia, Canada
Kennedy, A. M., Black, S., Watt, S., Vitkin, N., Young, J., Reeves, R., Salway, T.
10.1101/2022.02.18.22271151 — Posted: 2022-02-25
A mixture model to estimate SARS-CoV-2 seroprevalence in Chennai, India
Hitchings, M. D. T., Patel, E. U., Khan, R., Srikrishnan, A. K., Anderson, M., Kumar, K. S., Wesolowski, A. P., Iqbal, S. H., Rodgers, M. A., Mehta, S. H., Cloherty, G., Cummings, D. A. T., Solomon, S. S.
10.1101/2022.02.24.22271002 — Posted: 2022-02-25
Risk of COVID-19 related deaths for SARS-CoV-2 Omicron (B.1.1.529) compared with Delta (B.1.617.2)
Ward, I. L., Bermingham, C., Ayoubkhani, D., Gethings, O. J., Pouwels, K., Yates, T., Khunti, K., Hippisley-Cox, J., Banerjee, A., Walker, A. S., Nafilyan, V.
10.1101/2022.02.24.22271466 — Posted: 2022-02-25

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).